文献速递糖尿病肥胖与代谢综合征

SGLT2抑制剂对代谢、肾功能与血压的作用

The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
PubMed 文献 · Diabetologia · 2018-08-22

本文综述SGLT2抑制剂在肾脏近端小管抑制钠-葡萄糖共转运体2后,对肾功能、血浆容量稳态、脂肪与能量代谢的广泛影响。与安慰剂相比,SGLT2抑制剂使HbA1c降低7-10 mmol/mol(0.6-0.9%),降糖幅度与基线血糖浓度和肾小球滤过葡萄糖量成比例。SGLT2抑制后钠和葡萄糖溢出近端肾单位,触发能量代谢、肾滤过和血浆容量的动态可逆重调,长期影响脂肪、肾功能、血压及2型糖尿病患者健康与生存。

要点

  • SGLT2抑制剂主要用于2型糖尿病血糖控制,较安慰剂降低HbA1c 7-10 mmol/mol(0.6-0.9%)。
  • 降糖效果与基线血糖浓度和肾小球葡萄糖滤过成比例,血糖控制差和/或基线高滤过者可能更明显。
  • 无糖尿病者和eGFR降低者降糖效果减弱。

核心结论

  • SGLT2抑制剂对肾功能、血浆容量稳态、脂肪与能量代谢具有广泛影响,长期重调能量/盐/水平衡生理,影响2型糖尿病患者的脂肪、肾功能、血压及健康与生存。

研究设计与样本

  • 本文为综述,检索范围未在原文中明确报告。

主要发现

  • 与安慰剂相比,SGLT2抑制剂使HbA1c降低7-10 mmol/mol(0.6-0.9%)。
  • 降糖活性与环境中葡萄糖浓度和肾小球对该葡萄糖的滤过成比例,血糖控制差和/或基线高滤过者可能降糖更明显。
  • 无糖尿病者和eGFR降低者中SGLT2抑制剂的降糖效果减弱。
  • SGLT2抑制后钠和葡萄糖溢出近端肾单位,触发能量代谢、肾滤过和血浆容量的动态可逆重调,不依赖尿中丢失。
  • 上述过程可在无明显糖尿或持续利钠的情况下观察到。

关键数值与推荐

  • 与安慰剂相比,SGLT2抑制剂使HbA1c降低7-10 mmol/mol(0.6-0.9%)。

临床怎么用

  • SGLT2抑制剂主要用于2型糖尿病血糖控制。
  • 降糖效果与基线血糖浓度和肾小球葡萄糖滤过成比例,血糖控制差和/或基线高滤过者可能更明显。
  • 无糖尿病者和eGFR降低者降糖效果减弱。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inhibition of the sodium-glucose cotransporter (SGLT) 2 in the proximal tubule of the kidney has a broad range of effects on renal function and plasma volume homeostasis, as well as on adiposity and energy metabolism across the entire body. SGLT2 inhibitors are chiefly used in type 2 diabetes for glucose control, achieving reductions in HbA1c of 7-10 mmol/mol (0.6-0.9%) when compared with placebo. This glucose-lowering activity is proportional to the ambient glucose concentration and glomerular filtration of this glucose, so may be greater in those with poor glycaemic control and/or hyperfiltration at baseline. Equally, the glucose-lowering effects of SGLT2 inhibitors are attenuated in individuals without diabetes and those with a reduced eGFR. However, unlike the glucose-lowering effects of SGLT2 inhibitors, the spill-over of sodium and glucose beyond the proximal nephron following SGLT2 inhibition triggers dynamic and reversible realignment of energy metabolism, renal filtration and plasma volume without relying on losses into the urine. In addition, these processes are observed in the absence of significant glucosuria or ongoing natriuresis. In the long term, the resetting of energy/salt/water physiology following SGLT2 inhibition has an impact, not only on adiposity, renal function and blood pressure control, but also on the health and survival of patients with type 2 diabetes. A better understanding of the precise biology underlying the acute actions of SGLT2 inhibitors in the kidney and how they are communicated to the rest of the body will likely lead to improved therapeutics that augment similar pathways in individuals with, or even without, diabetes to achieve additional benefits.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018. PMID: 30132034. doi:10.1007/s00125-018-4669-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。